文章：

美国肝细胞癌患者接受阿特珠单抗与贝伐珠单抗联合治疗后的真实世界系统性治疗模式分析

Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States

原文发布日期：22 November 2023

DOI: 10.3390/cancers15235532

类型: Article

开放获取: 是

英文摘要：

Real-world (RW) evidence is needed to evaluate atezolizumab plus bevacizumab (atezo + bev) utilization for hepatocellular carcinoma (HCC) in clinical practice. This retrospective cohort study used administrative claims databases to evaluate treatment patterns in individuals with HCC ≥18 years of age who were initiated on atezo + bev between June 2020 and June 2022. The endpoints of this study were the proportion of individuals who discontinued atezo + bev and received subsequent systemic therapies, time to discontinuation (TTD), and time to next treatment. Overall, 825 individuals were eligible (median age 67 years; 80% male). Over a median follow-up of 15.3 months, most (72%) discontinued atezo + bev, with a median TTD of 3.5 months. A minority (19%) received subsequent therapies, with the most common second-line agents being lenvatinib (6%), cabozantinib (4%), and nivolumab (4%). The median time from index to next treatment post-atezo + bev was 5.4 months. Further research is needed to identify the patients who are most likely to benefit from atezo + bev as well as later-line HCC therapies to optimize overall survival.

摘要翻译： 

为评估阿特珠单抗联合贝伐珠单抗（atezo + bev）在肝细胞癌（HCC）临床实践中的应用情况，需要获取真实世界（RW）证据。本回顾性队列研究利用行政理赔数据库，对2020年6月至2022年6月期间开始接受atezo + bev治疗的18岁及以上HCC患者的治疗模式进行评估。研究终点包括停用atezo + bev并接受后续系统治疗的患者比例、停药时间（TTD）以及至下次治疗时间。研究共纳入825例符合条件的患者（中位年龄67岁；80%为男性）。在中位随访15.3个月期间，大多数患者（72%）停用了atezo + bev，中位TTD为3.5个月。少数患者（19%）接受了后续治疗，最常见的二线药物为仑伐替尼（6%）、卡博替尼（4%）和纳武利尤单抗（4%）。从开始atezo + bev治疗至后续治疗的中位时间为5.4个月。未来需进一步研究以明确最可能从atezo + bev及后线HCC治疗中获益的患者群体，从而优化患者总生存期。

原文链接：

Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States